Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC
Decision Date | 03 July 2019 |
Docket Number | 2017-2508 |
Citation | 927 F.3d 1333 (Mem) |
Parties | ATHENA DIAGNOSTICS, INC., Oxford University Innovation LTD., Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Plaintiffs-Appellants v. MAYO COLLABORATIVE SERVICES, LLC, dba Mayo Medical Laboratories, Mayo Clinic, Defendants-Appellees |
Court | U.S. Court of Appeals — Federal Circuit |
A petition for rehearing en banc was filed by appellants Athena Diagnostics, Inc., Oxford University Innovation Ltd., and the Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. A response to the petition was invited by the court and filed by appellees Mayo Collaborative Services, LLC and Mayo Clinic. Several motions for leave to file amici curiae briefs were filed and granted by the court. The petition for rehearing, response, and amici curiae briefs were first referred to the panel that heard the appeal, and thereafter, to the circuit judges who are in regular active service. A poll was requested, taken, and failed.
I concur in the court's decision not to rehear this case en banc. In my view, we can accomplish little in doing so, as we are bound by the Supreme Court's decision in Mayo. Some of us have already expressed our concerns over current precedent. E.g. , Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC , 915 F.3d 743, 753 n.4 (Fed. Cir. 2019) ; Ariosa Diagnostics, Inc. v. Sequenom, Inc. , 809 F.3d 1282, 1284 (Fed. Cir. 2015) ( ); id. at 1287 ( ).
If I could write on a clean slate, I would write as an exception to patent eligibility, as respects natural laws, only claims directed to the natural law itself, e.g. , E=mc2, F=ma, Boyle's Law, Maxwell's Equations, etc. I would not exclude uses or detection of natural laws. The laws of anticipation, obviousness, indefiniteness, and written description provide other filters to determine what is patentable.
But we do not write here on a clean slate; we are bound by Supreme Court precedent. In Mayo Collaborative Services v. Prometheus Laboratories, Inc. , the claims at issue were held by the Court to be directed to the relationship between the concentration of metabolites in the blood and the likelihood that a drug dose will be ineffective, which it referred to as a law of nature. 566 U.S. 66, 74–75, 77, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012). The other steps—administering a drug and detecting the level of a specific metabolite—added only "[p]urely ‘conventional or obvious’ ‘[pre]-solution activity’ " that was "not sufficient to transform an unpatentable law of nature into a patent-eligible application of such a law." Id. at 79, 132 S.Ct. 1289 ( )(quoting Parker v. Flook , 437 U.S. 584, 590, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978) ); see Bilski v. Kappos , 561 U.S. 593, 610–11, 130 S.Ct. 3218, 177 L.Ed.2d 792 (2010) ; Flook , 437 U.S. at 590, 98 S.Ct. 2522 (). Because the claims recited only what the Court called a natural law together with well-understood, conventional activity, the Court concluded the claims were ineligible under § 101. Mayo , 566 U.S. at 73, 79–80, 132 S.Ct. 1289.
In applying Mayo , we have accordingly held claims focused on detecting new and useful natural laws with conventional steps to be ineligible. E.g. , Cleveland Clinic Found. v. True Health Diagnostics LLC , 859 F.3d 1352, 1363 (Fed. Cir. 2017), cert. denied , ––– U.S. ––––, 138 S. Ct. 2621, 201 L.Ed.2d 1026 (2018) ; Ariosa Diagnostics, Inc. v. Sequenom, Inc. , 788 F.3d 1371, 1378 (Fed. Cir. 2015), cert. denied , ––– U.S. ––––, 136 S. Ct. 2511, 195 L.Ed.2d 841 (2016). In Cleveland Clinic , the claims recited a specific assay to detect the protein MPO, the enzyme-linked immunosorbent assay. 859 F.3d at 1357–58, 1362. Ariosa similarly involved a specific technique to amplify and detect DNA, the polymerase chain reaction. 788 F.3d at 1377. But in both cases, the patents' specifications described these techniques as well-understood and conventional. Cleveland Clinic , 859 F.3d at 1355 ; Ariosa , 788 F.3d at 1377. We concluded that using these routine assays to detect new natural phenomena did not transform the claims into patent eligible applications. Cleveland Clinic , 859 F.3d at 1362–63 ; Ariosa , 788 F.3d at 1376–77.
In contrast, new method of treatment patents do not fall prey to Mayo discovery of what . the Supreme Court would call the natural law—the correlation between MuSK autoantibodies and the neurological disorder myasthenia gravis —but we cannot premise eligibility solely on the natural law's novelty. Mayo , 566 U.S. at 73, 132 S.Ct. 1289 ( ); Flook , 437 U.S. at 591–92, 98 S.Ct. 2522 ( ). Under Supreme Court precedent, I do not believe that specific yet purely conventional detection steps impart eligibility to a claim that otherwise only sets forth what the Court has held is a natural law. That is the situation presented in Ariosa , Cleveland Clinic , and now Athena . Accordingly, as long as the Court's precedent stands, the only possible solution lies in the pens of claim drafters or legislators. We are neither.
Amici and others have complained that our eligibility precedent is confused. However, our cases are consistent. They have distinguished between new method of treatment claims and unconventional laboratory techniques, on the one hand, and, on the other hand, diagnostic methods that consist of routine steps to observe the operation of a natural law, a clear line. Beyond that, I do not see a way clear to distinguish Mayo in a useful, principled, fashion. Software is another matter, but such patents are not before us here.
I therefore concur in the decision of the court not to take this case en banc because I do not believe we can convincingly distinguish Mayo in this case.
The multiple concurring and dissenting opinions regarding the denial of en banc rehearing in this case are illustrative of how fraught the issue of § 101 eligibility, especially as applied to medical diagnostics patents, is. I agree that the language in Mayo , as later reinforced in Alice , forecloses this court from adopting an approach or reaching a result different from the panel majority's. I also agree, however, that the bottom line for diagnostics patents is problematic. But this is not a problem that we can solve. As an inferior appellate court, we are bound by the Supreme Court.
I, for one, would welcome further explication of eligibility standards in the area of diagnostics patents. Such standards could permit patenting of essential life saving inventions based on natural laws while providing a reasonable and measured way to differentiate between overly broad patents claiming natural laws and truly worthy specific applications. Such an explication might come from the Supreme Court. Or it might come from Congress, with its distinctive role in making the factual and policy determinations relevant to setting the proper balance of innovation incentives under patent law.
In the realm of abstract ideas, the Mayo / Alice framework has successfully screened out claims that few would contend should be patent eligible, for example, those that merely apply well-known business methods and other processes using computers or the Internet.1 The Mayo / Alice framework has thus proven to be both valuable and effective at invalidating overly broad, non-inventive claims that would effectively "grant a monopoly over an abstract idea." Alice Corp. v. CLS Bank Int'l , 573 U.S. 208, 216, 134 S.Ct. 2347, 189 L.Ed.2d 296 (2014) (quoting Bilski v. Kappos , 561 U.S. 593, 611–612, 130 S.Ct. 3218, 177 L.Ed.2d 792 (2010) ). As the Supreme Court has recognized, the concern with such patents is that ...
To continue reading
Request your trial-
Am. Axle & Mfg., Inc. v. Neapco Holdings LLC
..."would prohibit all other persons from making the same thing by any means whatsoever."); Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC , 927 F.3d 1333, 1344–49 (Fed. Cir. 2019) (Chen, J., concurring in denial of rehearing en banc) (explaining how the Supreme Court in Mayo Colla......
-
PPS Data, LLC v. Jack Henry & Assocs., Inc.
...distinctive claim would artificially limit the scope of the patentee's property rights. See Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC , 927 F.3d 1333, 1342 (Fed. Cir. 2019). Professor Patricia Campbell explains how this artificial limitation may constitute a denial of due p......
-
Am. Axle & Mfg., Inc. v. Neapco Holdings LLC
...of linkage disequilibrium to the problem of detecting coding sequences of DNA"); Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC , 927 F.3d 1333, 1359 (Fed. Cir. 2019) (Moore, J., dissenting) (order denying petition for en banc rehearing) ("[T]he Supreme Court suggests we should ......
-
Illumina, Inc. v. Ariosa Diagnostics, Inc.
...consistently held diagnostic claims unpatentable as directed to ineligible subject matter. See Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC , 927 F.3d 1333, 1352 (Fed. Cir. 2019) (Moore, J., dissenting from denial of rehearing en banc ) ("Since Mayo , we have held every single......
-
Considerations For Innovators When Navigating Patent Eligibility On The International Stage
...Collaborative Services v. Prometheus Labs., Inc., 566 U.S. 66 (2012). 11. Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC., 927 F.3d 1333 (Fed. Cir. 2019) (denying en banc review with four concurrences and four 12. E.g., Guidelines for Examination in the European Patent Office, P......
-
Considerations For Innovators When Navigating Patent Eligibility On The International Stage
...Collaborative Services v. Prometheus Labs., Inc., 566 U.S. 66 (2012). 11. Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC., 927 F.3d 1333 (Fed. Cir. 2019) (denying en banc review with four concurrences and four 12. E.g., Guidelines for Examination in the European Patent Office, P......
-
A New Frontier in Patent Bar Ethics?
...and, therefore, the claims were not invalid. Patentable Subject Matter Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC , 927 F.3d 1333, 2019 U.S.P.Q.2d 246748 (Fed. Cir. 2019). The Federal Circuit denied the petition for panel rehearing and the John C. Gatz is a member of the f......
-
An Interview with Li-Hsien (Lily) Rin-Laures
...and, therefore, the claims were not invalid. Patentable Subject Matter Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC , 927 F.3d 1333, 2019 U.S.P.Q.2d 246748 (Fed. Cir. 2019). The Federal Circuit denied the petition for panel rehearing and the John C. Gatz is a member of the f......
-
The 'Essence' of an Invention Is as Important as the Claims
...6. Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 573 U.S. 208 (2014). 7. E.g. , Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 927 F.3d 1333, 1348 (Fed. Cir. 2019) (Dyk, J., concurring); Intellectual Ventures I LLC v. Erie Indem. Co., 850 F.3d 1315, 1328 (Fed. Cir. 2017). 8. Interne......
-
Patenting Nature
...and, therefore, the claims were not invalid. Patentable Subject Matter Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC , 927 F.3d 1333, 2019 U.S.P.Q.2d 246748 (Fed. Cir. 2019). The Federal Circuit denied the petition for panel rehearing and the John C. Gatz is a member of the f......